Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Jennifer R. Brown, Filippo Utro et al.|Blood Advances|2022Cited by 79
Bad to the BoneJennifer L. Crombie, David C. Fisher, Ramkumar Venkateswaran et al.|New England Journal of Medicine|2019Cited by 0